tetano
Editor, Senior Moderator
J Infect Public Health
. 2022 Nov 29;16(1):80-89.
doi: 10.1016/j.jiph.2022.11.029. Online ahead of print.
First case series and literature review of coronavirus disease 2019 (COVID-19) associated pulmonary tuberculosis in Southeast Asia: Challenges and opportunities
Noppachai Siranart[SUP] 1 [/SUP], Walit Sowalertrat[SUP] 1 [/SUP], Manichaya Sukonpatip[SUP] 1 [/SUP], Gompol Suwanpimolkul[SUP] 2 [/SUP], Pattama Torvorapanit[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Subclinical tuberculosis (TB) is accidentally detected by radiologic and microbiologic findings. Transmission by those with subclinical TB could delay prevention effort. However, our study demonstrated positive aspect of COVID-19 outbreak as it could allow subclinical TB to be detected faster through a chest X-Ray (CXR).
Methods: This cross-sectional cohort study aimed to report demographics, comorbidities, and outcomes related to early detection of TB among COVID-19 patients, and to elaborate the association between SARS-CoV-2 and pulmonary TB. Data of patients with SARS-CoV-2 co-infection with Mycobacterium tuberculosis (MTB) diagnosed between March 2020 - March 2022 was collected.
Results: Out of 12,275 COVID-19 patients, 26 were definitively diagnosed with MTB infection (mean age 48.16 ± 20.17 years). All cases that had suspicious CXR that were not typical for COVID-19, were tested for MTB. On average, pulmonary TB was diagnosed after admission 5(3-10) days, the treatment initiation period was 3(1-5) days from the TB diagnosis.
Conclusions: This suggests an early detection of tuberculosis among COVID-19 patients by quicker screening CXR and sputum comparing to previous symptom guided screening. Thereby reducing the chance of TB transmission demonstrated during COVID-19 pandemic. So, clinicians should be aware of pulmonary tuberculosis in COVID-19 patients with atypical radiologic findings.
Keywords: COVID-19; Mycobacterium tuberculosis; SARS-CoV-2; Subclinical tuberculosis.
. 2022 Nov 29;16(1):80-89.
doi: 10.1016/j.jiph.2022.11.029. Online ahead of print.
First case series and literature review of coronavirus disease 2019 (COVID-19) associated pulmonary tuberculosis in Southeast Asia: Challenges and opportunities
Noppachai Siranart[SUP] 1 [/SUP], Walit Sowalertrat[SUP] 1 [/SUP], Manichaya Sukonpatip[SUP] 1 [/SUP], Gompol Suwanpimolkul[SUP] 2 [/SUP], Pattama Torvorapanit[SUP] 3 [/SUP]
Affiliations
- PMID: 36495816
- DOI: 10.1016/j.jiph.2022.11.029
Abstract
Background: Subclinical tuberculosis (TB) is accidentally detected by radiologic and microbiologic findings. Transmission by those with subclinical TB could delay prevention effort. However, our study demonstrated positive aspect of COVID-19 outbreak as it could allow subclinical TB to be detected faster through a chest X-Ray (CXR).
Methods: This cross-sectional cohort study aimed to report demographics, comorbidities, and outcomes related to early detection of TB among COVID-19 patients, and to elaborate the association between SARS-CoV-2 and pulmonary TB. Data of patients with SARS-CoV-2 co-infection with Mycobacterium tuberculosis (MTB) diagnosed between March 2020 - March 2022 was collected.
Results: Out of 12,275 COVID-19 patients, 26 were definitively diagnosed with MTB infection (mean age 48.16 ± 20.17 years). All cases that had suspicious CXR that were not typical for COVID-19, were tested for MTB. On average, pulmonary TB was diagnosed after admission 5(3-10) days, the treatment initiation period was 3(1-5) days from the TB diagnosis.
Conclusions: This suggests an early detection of tuberculosis among COVID-19 patients by quicker screening CXR and sputum comparing to previous symptom guided screening. Thereby reducing the chance of TB transmission demonstrated during COVID-19 pandemic. So, clinicians should be aware of pulmonary tuberculosis in COVID-19 patients with atypical radiologic findings.
Keywords: COVID-19; Mycobacterium tuberculosis; SARS-CoV-2; Subclinical tuberculosis.